– NDA for etripamil in PSVT resubmitted in 1Q 2024 – Cash resources as of March 31, 2024 expected to fund operations into 2026 – Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing MONTREAL and CHARLOTTE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update. "We're currently on track for the potential FDA approval of CAR ...